Caribou Biosciences, IDT Announce Agreement
News Feb 24, 2016
Caribou Biosciences, Inc. and Integrated DNA Technologies, Inc. (IDT) have entered into a non-exclusive license agreement under which Caribou has granted IDT worldwide rights to commercialize CRISPR-Cas9 reagents under Caribou’s intellectual property. The license is subject to a research use limited label.
“We are proud to partner with Integrated DNA Technologies, a prominent leader in the field of nucleic acid–based technologies,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “This partnership will help provide researchers with the tools they need to conduct effective CRISPR-Cas9 research.”
Joseph Walder, M.D., Ph.D., President and Chief Executive Officer of IDT, said, “IDT is excited to be the first genomics company to have reached this agreement with Caribou, a recognized leader in the field of CRISPR-Cas9 research. This license allows us to deliver the entire spectrum of products for CRISPR-Cas9 genome editing, solidifying our position at the forefront of this groundbreaking technology.”
IDT’s CRISPR-Cas9 reagents will be used by customers conducting biological research across a broad range of scientific areas such as drug discovery, plant biology, and genomics. IDT’s CRISPR-Cas9 reagents will provide researchers with the ability to edit genomic DNA precisely and efficiently.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018